Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Improved financials
Launch excellence
> High-value innovation
Operational excellence
Strengthen foundations
Conclusion
Abbreviations
3. High-value innovation
Industry-leading development engine; now prioritizing value per asset
Total NME approvals by company (1999-2021)1
42
30
NDA
34
✓
Prioritization: Active prioritization for core
Therapeutic Areas
Commercial focus: Increased commercial
input into R&D
Development/TPP: US TPP prioritized,
portfolio prioritization focusing on high-value
assets
Operational efficiency: Strengthen efficiency
by simplifying structures; further integrating
R&D to accelerate key early assets
People: Maintain/strengthen high-performing
organization of competent and engaged talent
28
23
18
✓
14
12
BLA
✓
Novartis
Company A Company B Company C Company D Company E
1. US FDA NME approvals
20
Novartis Investor Presentation | September 22, 2022
U |
NOVARTIS | Reimagining MedicineView entire presentation